Prospective study of /sup 123/I-labeled monoclonal antibody imaging in ovarian cancer
Thirty patients presenting with a pelvic mass were entered into a prospective study on the use of radioimmunoscintigraphy with the /sup 123/I-labeled monoclonal antibody HMFG2. The imaging data was obtained without knowledge of the clinical data and compared with subsequent surgical findings. A false-positive diagnosis of ovarian cancer was made in five of ten patients subsequently shown not to have ovarian cancer; thus the technique cannot be used as a screening test. A true-positive diagnosis was made in 19 out of 20 patients shown subsequently to have ovarian cancer. In 18 of these patients the distribution of uptake closely fitted the surgical findings. Methods of improving these results are described. In conclusion, radioimmunoscintigraphy is of no use in determining whether a pelvic mass is due to ovarian cancer, but has benefit in the evaluation of chemotherapy and may, in the future, prevent the need for second-look operations in some circumstances.
- Research Organization:
- St. Bartholomew's Hospital, London, England
- OSTI ID:
- 5653731
- Journal Information:
- J. Clin. Oncol.; (United States), Journal Name: J. Clin. Oncol.; (United States) Vol. 5; ISSN JCOND
- Country of Publication:
- United States
- Language:
- English
Similar Records
/sup 123/I radioiodinated antibody imaging of occult ovarian cancer
Radioimmunodiagnosis of ovarian cancer using /sup 123/I-labelled, tumor-associated monoclonal antibodies
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BODY
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
FEMALE GENITALS
GONADS
INTERMEDIATE MASS NUCLEI
IODINE 125
IODINE ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LABELLED COMPOUNDS
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
ORGANS
OVARIES
PATIENTS
RADIOISOTOPE SCANNING
RADIOISOTOPES
SCINTISCANNING
TRACER TECHNIQUES